Solara Pharma Hits Day High as Q1 Profit Jumps 55%

July 23, 2026July 23, 2026

Solara Active Pharma shares touched a day high of Rs 574, after the company’s Q1 net profit jumped 55% year on year to Rs 16.3 crore.

Revenue for the quarter grew nearly 20% to Rs 382 crore, up from Rs 319 crore a year earlier. Operating profit, or EBITDA, rose too, up 10% to Rs 62.6 crore, though the margin actually narrowed a bit, from 17.8% to 16.4%.

The company said higher raw material costs, tied to ongoing tensions in West Asia, ate into some of the gains.

Not every part of the business is doing well, though. Solara Ibuprofen unit, which makes a commodity version of the common painkiller, keeps losing money.

It posted a negative EBITDA margin of 12% for the quarter, and the company says it’s now working with bankers to figure out what to do with it, whether that’s a sale, restructuring or something else, with a decision expected by the end of the second quarter of this fiscal year.

Because of this, a separate plan to spin off its polymers and CRAMS businesses has been put on hold until the Ibuprofen question gets sorted. The rest of the business, what the company calls its base business, is in much better shape.

That segment brought in Rs 307.7 crore, up 24% year on year, with EBITDA rising 8% to Rs 72.2 crore. Solara also paid down Rs 134.6 crore of debt during the quarter, bringing net debt to Rs 479.5 crore.

The stock’s reaction didn’t hold through the day. After touching that day high, shares fell back sharply and closed at Rs 523.75, down 2.31%, or Rs 12.40, from the previous close of Rs 536.15.

Discover the next big investment! Tradz by EquityPandits’ IPO screener helps you identify promising initial public offerings. Download Tradz by EquityPandit and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!